JP2006306812A - 好酸球浸潤抑制剤 - Google Patents
好酸球浸潤抑制剤 Download PDFInfo
- Publication number
- JP2006306812A JP2006306812A JP2005133264A JP2005133264A JP2006306812A JP 2006306812 A JP2006306812 A JP 2006306812A JP 2005133264 A JP2005133264 A JP 2005133264A JP 2005133264 A JP2005133264 A JP 2005133264A JP 2006306812 A JP2006306812 A JP 2006306812A
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- dgla
- composition
- infiltration
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000008595 infiltration Effects 0.000 title claims abstract description 26
- 238000001764 infiltration Methods 0.000 title claims abstract description 26
- 239000003112 inhibitor Substances 0.000 title description 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 claims abstract description 49
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 claims abstract description 49
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 20
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 claims abstract description 6
- 210000003979 eosinophil Anatomy 0.000 claims description 38
- 235000013305 food Nutrition 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 14
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 10
- 201000008937 atopic dermatitis Diseases 0.000 claims description 10
- 208000023504 respiratory system disease Diseases 0.000 claims description 9
- 208000017520 skin disease Diseases 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000010643 digestive system disease Diseases 0.000 claims description 5
- 125000005456 glyceride group Chemical group 0.000 claims description 5
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000010668 atopic eczema Diseases 0.000 claims description 4
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims description 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 4
- 235000021588 free fatty acids Nutrition 0.000 claims description 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 4
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 4
- 244000005700 microbiome Species 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 201000009732 pulmonary eosinophilia Diseases 0.000 claims description 4
- 229930186217 Glycolipid Natural products 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 125000005457 triglyceride group Chemical group 0.000 claims description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 24
- 239000003921 oil Substances 0.000 description 15
- 235000019198 oils Nutrition 0.000 description 15
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 14
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 14
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 14
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 13
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 13
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 13
- 229940090949 docosahexaenoic acid Drugs 0.000 description 12
- 201000004624 Dermatitis Diseases 0.000 description 9
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 6
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 235000020940 control diet Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- -1 diglyceride Chemical compound 0.000 description 4
- 230000037406 food intake Effects 0.000 description 4
- 150000002617 leukotrienes Chemical class 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 4
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- 241000235575 Mortierella Species 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 235000021342 arachidonic acid Nutrition 0.000 description 3
- 229940114079 arachidonic acid Drugs 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 235000020778 linoleic acid Nutrition 0.000 description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 229940124446 critical care medicine Drugs 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000002444 effect on eosinophils Effects 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000005417 food ingredient Substances 0.000 description 2
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000010525 oxidative degradation reaction Methods 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- MWLSOWXNZPKENC-UHFFFAOYSA-N zileuton Chemical compound C1=CC=C2SC(C(N(O)C(N)=O)C)=CC2=C1 MWLSOWXNZPKENC-UHFFFAOYSA-N 0.000 description 2
- 229940052267 zyflo Drugs 0.000 description 2
- PEYUIKBAABKQKQ-AFHBHXEDSA-N (+)-sesamin Chemical compound C1=C2OCOC2=CC([C@H]2OC[C@H]3[C@@H]2CO[C@@H]3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-AFHBHXEDSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102100034544 Acyl-CoA 6-desaturase Human genes 0.000 description 1
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 1
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 239000004970 Chain extender Substances 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010037138 Linoleoyl-CoA Desaturase Proteins 0.000 description 1
- 241000907999 Mortierella alpina Species 0.000 description 1
- 241000235388 Mucorales Species 0.000 description 1
- 206010029098 Neoplasm skin Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000233639 Pythium Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 235000021336 beef liver Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000021316 daily nutritional intake Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000004710 electron pair approximation Methods 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- PEYUIKBAABKQKQ-UHFFFAOYSA-N epiasarinin Natural products C1=C2OCOC2=CC(C2OCC3C2COC3C2=CC=C3OCOC3=C2)=C1 PEYUIKBAABKQKQ-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ITNKVODZACVXDS-YNUSHXQLSA-N ethyl (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoate Chemical compound CCOC(=O)CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC ITNKVODZACVXDS-YNUSHXQLSA-N 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000007302 negative regulation of cytokine production Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 208000024696 nocturnal asthma Diseases 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 235000015067 sauces Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- VRMHCMWQHAXTOR-CMOCDZPBSA-N sesamin Natural products C1=C2OCOC2=CC([C@@H]2OC[C@@]3(C)[C@H](C=4C=C5OCOC5=CC=4)OC[C@]32C)=C1 VRMHCMWQHAXTOR-CMOCDZPBSA-N 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005133264A JP2006306812A (ja) | 2005-04-28 | 2005-04-28 | 好酸球浸潤抑制剤 |
| EP19183855.6A EP3581178B1 (en) | 2005-02-14 | 2006-02-10 | Composition containing dihomo-(gamma)-linolenic acid (dgla) as active ingredient |
| CA2599112A CA2599112C (en) | 2005-02-14 | 2006-02-10 | Composition comprising dihomo-.gamma.-linolenic acid (dgla) as the active ingredient |
| PCT/JP2006/302787 WO2006085687A1 (ja) | 2005-02-14 | 2006-02-10 | ジホモ−γ−リノレン酸（ＤＧＬＡ）を有効成分として含んで成る組成物 |
| US11/884,199 US9006287B2 (en) | 2005-02-14 | 2006-02-10 | Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient |
| EP06713928.7A EP1852114B1 (en) | 2005-02-14 | 2006-02-10 | Composition containing dihomo-y-linolenic acid (dgla) as active ingredient |
| CN2012100164426A CN102600174A (zh) | 2005-02-14 | 2006-02-14 | 含有有效成分二均-γ-亚麻酸(DGLA)的组成物 |
| CN 200610003112 CN101019853B (zh) | 2005-02-14 | 2006-02-14 | 含有有效成分二均-γ-亚麻酸(DGLA)的组成物 |
| US14/644,231 US9943495B2 (en) | 2005-02-14 | 2015-03-11 | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient |
| US15/911,806 US10342773B2 (en) | 2005-02-14 | 2018-03-05 | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005133264A JP2006306812A (ja) | 2005-04-28 | 2005-04-28 | 好酸球浸潤抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006306812A true JP2006306812A (ja) | 2006-11-09 |
| JP2006306812A5 JP2006306812A5 (enExample) | 2008-03-27 |
Family
ID=37474109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005133264A Pending JP2006306812A (ja) | 2005-02-14 | 2005-04-28 | 好酸球浸潤抑制剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2006306812A (enExample) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006306813A (ja) * | 2005-04-28 | 2006-11-09 | Suntory Ltd | 肥満細胞増殖抑制剤 |
| WO2013057284A1 (en) * | 2011-10-19 | 2013-04-25 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof |
| US9006287B2 (en) | 2005-02-14 | 2015-04-14 | Suntory Holdings Limited | Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient |
| US9216151B2 (en) | 2009-04-29 | 2015-12-22 | Dignity Sciences Limited. | Use of PUFAS for treating skin inflammation |
| US10105333B2 (en) | 2014-06-04 | 2018-10-23 | Ds Biopharma Limited | Pharmaceutical compositions comprising DGLA and use of same |
| WO2021065659A1 (ja) | 2019-10-01 | 2021-04-08 | サントリーホールディングス株式会社 | アクアポリン３の発現調節を介した腸機能改善用組成物及びその使用 |
| US12076304B2 (en) | 2020-04-03 | 2024-09-03 | Afimmune Limited | Compositions comprising 15-HEPE and methods of treating or preventing hematologic disorders, and/or related diseases |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59152324A (ja) * | 1983-02-01 | 1984-08-31 | エフア−モル・リミテツド | 医薬または健康食品組成物 |
| JPH02149508A (ja) * | 1988-03-22 | 1990-06-08 | Efamol Ltd | 皮膚改善用組成物とその方法 |
| JPH04244023A (ja) * | 1991-01-29 | 1992-09-01 | Idemitsu Petrochem Co Ltd | ω６系不飽和脂肪酸含有薬剤 |
| JPH06128154A (ja) * | 1978-01-23 | 1994-05-10 | Efamol Ltd | 食品組成物 |
| JPH06197735A (ja) * | 1979-05-18 | 1994-07-19 | Efamol Ltd | 食品組成物 |
| JP2002047176A (ja) * | 2000-08-04 | 2002-02-12 | Idemitsu Technofine Co Ltd | ＩｇＥ産生抑制剤 |
| JP2006219454A (ja) * | 2005-02-14 | 2006-08-24 | Suntory Ltd | 皮膚疾患経口治療または予防剤 |
| JP2006306813A (ja) * | 2005-04-28 | 2006-11-09 | Suntory Ltd | 肥満細胞増殖抑制剤 |
-
2005
- 2005-04-28 JP JP2005133264A patent/JP2006306812A/ja active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06128154A (ja) * | 1978-01-23 | 1994-05-10 | Efamol Ltd | 食品組成物 |
| JPH06197735A (ja) * | 1979-05-18 | 1994-07-19 | Efamol Ltd | 食品組成物 |
| JPS59152324A (ja) * | 1983-02-01 | 1984-08-31 | エフア−モル・リミテツド | 医薬または健康食品組成物 |
| JPH02149508A (ja) * | 1988-03-22 | 1990-06-08 | Efamol Ltd | 皮膚改善用組成物とその方法 |
| JPH04244023A (ja) * | 1991-01-29 | 1992-09-01 | Idemitsu Petrochem Co Ltd | ω６系不飽和脂肪酸含有薬剤 |
| JP2002047176A (ja) * | 2000-08-04 | 2002-02-12 | Idemitsu Technofine Co Ltd | ＩｇＥ産生抑制剤 |
| JP2006219454A (ja) * | 2005-02-14 | 2006-08-24 | Suntory Ltd | 皮膚疾患経口治療または予防剤 |
| JP2006306813A (ja) * | 2005-04-28 | 2006-11-09 | Suntory Ltd | 肥満細胞増殖抑制剤 |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9943495B2 (en) | 2005-02-14 | 2018-04-17 | Suntory Holdings Limited | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient |
| US10342773B2 (en) | 2005-02-14 | 2019-07-09 | Suntory Holdings Limited | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient |
| US9006287B2 (en) | 2005-02-14 | 2015-04-14 | Suntory Holdings Limited | Composition comprising dihomo-γ-linolenic acid (DGLA) as active ingredient |
| JP2006306813A (ja) * | 2005-04-28 | 2006-11-09 | Suntory Ltd | 肥満細胞増殖抑制剤 |
| US10328046B2 (en) | 2009-04-29 | 2019-06-25 | Ds Biopharma Limited | Topical compositions comprising polyunsaturated fatty acids |
| US10918614B2 (en) | 2009-04-29 | 2021-02-16 | Ds Biopharma Limited | Topical compositions comprising polyunsaturated fatty acids |
| US9439850B2 (en) | 2009-04-29 | 2016-09-13 | Dignity Sciences Limited | Use of pufas for treating skin inflammation |
| US9889106B2 (en) | 2009-04-29 | 2018-02-13 | Ds Biopharma Limited | Topical compositions comprising polyunsaturated fatty acids |
| US9216151B2 (en) | 2009-04-29 | 2015-12-22 | Dignity Sciences Limited. | Use of PUFAS for treating skin inflammation |
| US9421163B2 (en) | 2009-04-29 | 2016-08-23 | Dignity Sciences Limited | Topical compositions comprising polyunsaturated fatty acids |
| US9056086B2 (en) | 2011-10-19 | 2015-06-16 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA, 15-HEPE, and/or 15-HETrE and methods of use thereof |
| WO2013057284A1 (en) * | 2011-10-19 | 2013-04-25 | Dignity Sciences Limited | Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof |
| US10537543B2 (en) | 2014-06-04 | 2020-01-21 | Ds Biopharma Limited | Pharmaceutical compositions comprising DGLA and use of same |
| US10849870B2 (en) | 2014-06-04 | 2020-12-01 | Ds Biopharma Limited | Pharmaceutical compositions comprising DGLA and use of same |
| US10105333B2 (en) | 2014-06-04 | 2018-10-23 | Ds Biopharma Limited | Pharmaceutical compositions comprising DGLA and use of same |
| US11478442B2 (en) | 2014-06-04 | 2022-10-25 | Ds Biopharma Limited | Pharmaceutical compositions comprising DGLA and use of same |
| WO2021065659A1 (ja) | 2019-10-01 | 2021-04-08 | サントリーホールディングス株式会社 | アクアポリン３の発現調節を介した腸機能改善用組成物及びその使用 |
| CN114585355A (zh) * | 2019-10-01 | 2022-06-03 | 三得利控股株式会社 | 借由水通道蛋白3的表达调节的肠功能改善用组合物及其应用 |
| TWI878353B (zh) * | 2019-10-01 | 2025-04-01 | 日商三得利控股股份有限公司 | 經由調節水通道蛋白３之表現的腸機能改善用組成物及其使用 |
| US12076304B2 (en) | 2020-04-03 | 2024-09-03 | Afimmune Limited | Compositions comprising 15-HEPE and methods of treating or preventing hematologic disorders, and/or related diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10342773B2 (en) | Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient | |
| Kroes et al. | A review of the safety of DHA45-oil | |
| EP1307107B1 (en) | Oil/fat composition | |
| JP4031219B2 (ja) | 油脂組成物 | |
| JP2002053892A (ja) | 油脂組成物 | |
| JP5546087B2 (ja) | 皮膚疾患経口治療または予防剤 | |
| Saidaiah et al. | A comprehensive review of Omega-3 fatty acids: Sources, industrial applications, and health benefits | |
| JP2016185973A (ja) | メタボリックシンドローム改善剤 | |
| Li et al. | Macronutrient innovations: the role of fats and sterols in human health | |
| JP2006306812A (ja) | 好酸球浸潤抑制剤 | |
| JP2006306813A (ja) | 肥満細胞増殖抑制剤 | |
| JP2007099633A (ja) | 脂質代謝改善用組成物 | |
| JP6203320B2 (ja) | 皮膚疾患経口治療または予防剤 | |
| Yamagata | Effects of dietary n-3 polyunsaturated fatty acids on cardiovascular disease | |
| JP2012082226A (ja) | 皮膚疾患経口治療または予防剤 | |
| JP6462790B2 (ja) | 皮膚疾患経口治療または予防剤 | |
| JP5479696B2 (ja) | 生体内のプラスマローゲン増加剤 | |
| JP6214474B2 (ja) | 皮膚疾患経口治療または予防剤 | |
| Wang et al. | Lipids and their impacts on health | |
| Hernandez et al. | Applications of omega-3 fats in foods | |
| Dhikav et al. | Omega-3 polyunsaturated fatty acid and cardiovascular disorders | |
| EP3750533A1 (en) | Agent for improving lymphatic circulation | |
| JP2002029967A (ja) | 月経前症候群症状緩和用食用油脂組成物 | |
| Anuaimy et al. | Future of Omega 3 in Nutrition | |
| WO2008153220A1 (ja) | 血管疾患の予防又は治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080212 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080212 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20090424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110524 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120124 |